Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trial.
Bianca GrosserJake EmmersonNic Gabriel ReitsamDavid CunninghamMatthew NankivellRuth E LangleyWilliam H AllumMartin TrepelBruno MärklHeike I GrabschPublished in: British journal of cancer (2023)
The SARIFA status has clinical utility as prognostic biomarker in oesophagogastric cancer patients irrespective of treatment modality. Whilst underlying biological mechanisms warrant further investigation, the SARIFA status might be used to identify new drug targets, potentially enabling repurposing of existing drugs targeting lipid metabolism.
Keyphrases
- clinical trial
- study protocol
- cardiac surgery
- patients undergoing
- phase iii
- cancer therapy
- cell migration
- phase ii
- randomized controlled trial
- locally advanced
- drug induced
- emergency department
- squamous cell carcinoma
- radiation therapy
- combination therapy
- drug delivery
- adverse drug
- open label
- rectal cancer
- smoking cessation
- double blind